Baricitinib in Patients with Refractory Rheumatoid Arthritis.
about
Emerging Therapies for Rheumatoid ArthritisImportance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.Future therapeutic targets in rheumatoid arthritis?Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Filgotinib for the treatment of rheumatoid arthritis.Efficacy of baricitinib in the treatment of rheumatoid arthritis.Investigational Janus kinase inhibitors in development for myelofibrosis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.JAK inhibition in inflammatory bowel disease.Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.Baricitinib for the treatment of rheumatoid arthritis.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.Challenges to develop novel anti-inflammatory and analgesic drugs.Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.JAK inhibitors in dermatology: The promise of a new drug class.Baricitinib: First Global Approval.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Advances of small molecule targeting of kinases.Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentHerpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.Validation and reliability of the Timed Up and Go test for measuring objective functional impairment in patients with long-standing rheumatoid arthritis: a cross-sectional study.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.Targeted inhibition of Janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes.
P2860
Q28078943-F2D512ED-C463-417A-B44D-79C55E4DF650Q30313218-96CEAC09-82B4-4406-A453-1644F3F7303DQ33841419-3A359161-542F-4E44-8292-DEFC6058719EQ34533379-611D5E02-695A-401D-8C94-C80C6024F879Q37484842-FA631BC7-8D16-4288-B50E-61F686257C35Q37604501-66FF6D74-47C2-48EC-A830-4BA3BB44478FQ37696609-CCF5204F-4228-4E4A-B2B4-5A88B1A2E537Q38372369-C6C5ADCF-DED4-4513-916E-2780C9D45454Q38609755-FA43C57D-F2B5-4601-8445-E64200821AB8Q38652849-DA5A87B0-84BC-44BE-A99F-E068C50247E3Q38691019-8051033B-5F0C-41F1-8D60-75C8B04637E7Q38751230-56354C9E-EC27-4DF7-BE5F-58B96A2F324FQ38761142-12AA4603-EFAB-4025-8997-67167686E9FDQ38821079-67E3D04A-592D-4691-B71C-80FA6955D7F3Q38840787-0C07E809-3FAA-4A05-8B24-14B7CDFA2116Q38932097-AC2F98AA-2229-4449-8BEE-2EBD95E62595Q38936622-3A2F0C46-7044-41D6-B602-398AD9DED554Q38941483-228C9E76-28B8-412C-8438-DC380B2FAE2EQ38941577-A8CBF832-45CF-4E9C-93CF-EDC55A470B80Q39020448-27CDC79A-3027-4E09-8D73-7650057A614CQ39068415-60A9F126-27EA-410F-998A-4BCECCFD60D4Q39111032-302ECCF4-6DFA-407F-A339-C282EC4DCF27Q39177156-71B94B43-84F5-4CBC-A097-1931571F5AACQ39230189-D03F8588-1211-4855-B599-C02D9D7E10ACQ39450797-7CDF7B21-F97E-4E71-B75D-8385BF0172A1Q40041736-CF2296FD-6420-4E93-9581-07533A726D75Q41704162-F4F8D05F-F3BC-4ADC-8F2C-777EC1D4E3EFQ41912068-718C294C-2B52-49F1-A5A9-C80A1508DCBDQ42356300-77BCE0E5-10B2-452C-9572-97C5B5B81383Q42701803-B9DD2BB3-20D6-435E-B596-DAEF1827F2A3Q47131401-08E7EB68-B1BC-4EB6-9864-A647F61D709FQ47132835-4E16339A-9484-45CE-A393-543B4B983A1FQ47360442-B588656D-55CB-4F43-A28D-7DAEE598B1EBQ47439880-788C3AD5-7752-4D7D-ACDC-AC5D7DFC6426Q47602038-B02EAAA5-DC4F-42B1-9E52-D361C0920A9EQ48542399-95A51FE1-8CC7-437D-89B1-827558BAE052Q48556502-37DAA3F7-4AB3-4034-874F-C6EEB193EE4BQ49724160-6600FBC2-B909-4EBF-8C05-45847EB2DD8BQ49792187-D402298A-65DB-44B8-A213-61253D63CF87Q49935507-1D5160A3-5C58-49DB-A124-8E0537DC2B73
P2860
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
@en
type
label
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
@en
prefLabel
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
@en
P2093
P356
P1476
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
@en
P2093
Alisa E Koch
Charles Ludivico
Douglas E Schlichting
Joel Kremer
Marek Krogulec
Mark C Genovese
Omid Zamani
Scott D Beattie
Stephanie de Bono
P304
P356
10.1056/NEJMOA1507247
P407
P577
2016-03-01T00:00:00Z